Q4 2022 consolidated revenue growth of 14.2% to $21.4 millionFY2022 revenue totaled $80.1 million or growth of ~15%, in line with guidanceFY2023 operating plan to focus on achieving positive Adjusted
Presentation at Conference on Retroviruses and Opportunistic Infections (CROI) demonstrates association between excess visceral abdominal fat (EVAF) reduction and decreased prevalence of metabolic syndrome with tesamorelin treatmentData provide further evidence
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.
Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Stock Market | FinancialContent Business Page financialcontent.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from financialcontent.com Daily Mail and Mail on Sunday newspapers.